The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


cgb by the numbers
More From The Market Online

Pro Medicus signs $43M, seven-year contract with Virtua Health in US

Pro Medicus' wholly-owned US subsidiary, Visage Imaging, has signed a seven-year, $43 million contract with Virtua…

Recce welcomes positive phase 3 clinical trial data for topical gel for diabetic foot ulcer infections

Recce Pharmaceuticals has reported a review of blinded data of its current phase 3 trial has…
Blood sample blood test blood concept

Newest ASX listee Identifai Genetics up +20% on IPO day eyeing prenatal screening disruption in the USA

The newest company to hit the ASX, Identifai Genetics (ASX:ID1), has seen its shares jump +20% on some...
Lung imaging concept

With the ASX in a better mood, 4D Medical climbs 7% back to $4.30/sh

4D Medical (ASX:4DX) appears to be back on investors’ radars on Monday as the stock climbed nearly +7% back